Navigation Links
Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial
Date:5/4/2009

ey at its TGA-approved manufacturing facilities. For more information about Pharmaxis, go to http://www.pharmaxis.com.au or contact Investor Relations on phone +61 2 9454 7200.

About Bronchitol

Pharmaxis Ltd is developing Bronchitol for the management of chronic obstructive lung diseases including cystic fibrosis, and bronchiectasis. Bronchitol is a proprietary dry-powder mannitol, precision formulated for delivery to the lungs through an easy-to-use, pocket-size, portable inhaler. Once inhaled its action on mucus helps restore normal lung clearance mechanisms. Clinical studies have shown Bronchitol to be effective and well tolerated in stimulating mucus hydration and clearance in people with chronic obstructive lung diseases. In particular, Bronchitol has been shown to increase mucus clearance from the lungs and significantly improve quality of life for people with bronchiectasis. Additional studies have also shown Bronchitol to improve lung function in people affected by cystic fibrosis.

About Cystic Fibrosis

In a healthy person, there is a constant flow of mucus over the surfaces of the air passages in the lungs, removing debris and bacteria. In CF, an inherited disease, a defective gene disrupts ion transport across the epithelial membrane within cells. In the lungs, this leads to a depletion of the airway surface liquid that normally bathes the cilia, and a resultant reduction in mucociliary clearance. The result is thick, sticky mucus that clogs the lungs, severely restricting the natural airway-clearing process. It also increases the potential for bacteria to become trapped and for inflammation, thus creating an unhealthy lung environment that leads to life- threatening lung infections.

Forward-Looking Statements

The statements contained in this media release that are not purely historic
'/>"/>

SOURCE Pharmaxis Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmaxis Announces Milestone in Phase III Trial for Cystic Fibrosis
2. Pharmaxis Announces New Drug Application Submission for Aridol(TM)
3. ASX/NASDAQ Media Release: Pharmaxis Files First Marketing Application for Bronchitol in Australia
4. Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial
5. Pharmaxis Establishes Named Patient Program for Bronchitol
6. Pharmaxis Long-Term Safety Study of Bronchitol Completes
7. Sirion Therapeutics Announces Clinical Data Presentations at the 2009 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
8. Optherion Announces Issuance of Canadian Patents Covering Age-Related Macular Degeneration Diagnostics and Treatments
9. Video: ev3 Inc. Announces First Patient Enrollments in DEFINITIVE LE Post-Market Study
10. Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients
11. Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Sept. 23, 2014 Research and ... "Physician Office Laboratory Markets, 3rd Edition" ... report, Physician Office Laboratory Markets is Kalorama,s complete ... industry. Physician office laboratories are diverse in their ... reimbursable, in-office pregnancy and glucose tests. Some specialty ...
(Date:9/23/2014)... , Sept. 23, 2014 This test can detect ... "risk event" is defined by activities that can transfer body ... or use of any shared needles. , An ... oral fluid. This HIV test works by looking for your ... results in 20 minutes, enabling patients to learn their status ...
(Date:9/23/2014)... 2014  Hill-Rom (NYSE: HRC ) today ... Renton, WA ), the nation,s third largest ... existing relationship as Hill-Rom now becomes Providence Health,s sole-source ... frame and surface products. Providence Health ... U.S.  It operates 34 hospitals, 475 physician clinics, 22 ...
Breaking Medicine Technology:Physician Office Laboratory Markets, 3rd Edition 2Physician Office Laboratory Markets, 3rd Edition 3WholeHealth Products announces the release of the FDA Cleared "HIV 1&2" Rapid Diagnostic Test for Professional and Retail 2Hill-Rom Announces Seven-Year, Sole-Source Contract with Providence Health 2
... (NASDAQ: SIAL ) today announced that its ... ), is introducing a novel CHOZN® GS-/- Zinc Finger ... for use in the production of biopharmaceuticals, the new ... glutamine synthetase (GS) knockout CHO cell line proven to ...
... LAS VEGAS, Oct. 26, 2011 Clinical Research Management, ... basic and applied research, clinical trials, and regulatory support, ... Boyer, Ph.D., will co-present a panel titled Battle ... the MAGI West Clinical Research Conference, October 23-26, 2011 ...
Cached Medicine Technology:SAFC Introduces the First Commercially Available Novel CHOZN® GS Knockout CHO Cell Line 2SAFC Introduces the First Commercially Available Novel CHOZN® GS Knockout CHO Cell Line 3SAFC Introduces the First Commercially Available Novel CHOZN® GS Knockout CHO Cell Line 4ClinicalRM to Co-Present Regulatory Compliance Panel at MAGI 2
(Date:9/23/2014)... As a consumer in today’s world, precautionary measures ... to trust testimonials that are supplied by the merchants ... customers into saying anything. , Consumer advocacy groups aim ... in depth coverage on a particular market i.e. nutrition. ... this issue and focus on exposing the thousands of ...
(Date:9/23/2014)... HealthDay Reporter TUESDAY, Sept. 23, 2014 (HealthDay ... breast milk is more likely than a blood transfusion to ... a new study finds. The researchers evaluated more than ... weighed 3.3 pounds or less and many who were born ... whether breast milk or transfusions carried the bigger risk. Infants ...
(Date:9/23/2014)... 23, 2014 (HealthDay News) -- A test used to diagnose ... where certain lung infections are more common, a new analysis ... is through the use of what,s known as functional imaging. ... FDG-PET is used, according to the study authors. Cancerous ... parts of the lungs that don,t have cancer, according ...
(Date:9/23/2014)... Genomic medicine is rapidly developing, bringing with its ... and optimize prevention and treatment interventions. Genetic ... immunodeficiency virus (HIV) and hepatitis c virus (HPC), ... be used to screen for an individual,s susceptibility ... treatments for addiction. , While there appear to ...
(Date:9/23/2014)... DC (PRWEB) September 23, 2014 ... care? The National Quality Forum (NQF) released ... ( http://www.qualityforum.org/WorkArea/linkit.aspx?LinkIdentifier=id&ItemID=77687 ), and an infographic ( http://bit.ly/1tX3lzA ... rising cost of healthcare, how patients define affordability, ... consumers to get the best possible healthcare at ...
Breaking Medicine News(10 mins):Health News:Consumer Health Reports Debuts Revolutionary Review Website 2Health News:Breast Milk a Risk for Spreading Common Virus to Preemies, Study Finds 2Health News:Breast Milk a Risk for Spreading Common Virus to Preemies, Study Finds 3Health News:Lung Infections May Hamper Ability to Detect Lung Cancer 2Health News:NYU-Mount Sinai Beth Israel study explores drug users' opinions on genetic testing 2Health News:Finding Affordable Care: Asking the Right Question is Key 2
... Enables PHNS and Healthcare Organizations to Audit, Enforce ... ... Regulations, BATON ROUGE, La., Nov. 16 TraceSecurity, a leading,provider ... its web-based Compliance Manager available to,hundreds of healthcare organizations across the ...
... to Improved HIV Management in Developing World, UPPSALA, ... has signed an agreement with a consortium of American ... of operational,funding, and has committed to raising additional funding ... Cavidi,s newly adopted three-year,business plan. Cavidi is the producer ...
... Agreement Ends Dispute Regarding Fee Disclosures for Separate ... ULLICO Inc. announced an,agreement resolving a Department of ... the Employee Retirement Income Security,Act of 1974 (ERISA). ... began as an inquiry,into ULLICO,s pension plan, ultimately ...
... Human Sexuality, Discussion on the Major Trends in Human Sexual Behavior, Sexual Desire, ... Sexual Dysfunction Issues, NEW YORK, Nov. 16 , WHAT: Are medicine and ... lead to better sex lives? What role does sex play in the ... and other compelling issues on human sexuality ...
... 16 HealthPartners,is the top-performing health plan in the ... newly released business report. The report, sponsored by the,National ... request for,information tool. The tool is used by purchasers ... Health Care Action Group, a coalition of,private and public ...
... November 15 - December 31, TULSA, Okla., Nov. ... today that it will offer three Medicare Part D,prescription ... eligible for Medicare. Medicare beneficiaries in Oklahoma can sign,up ... during the 2008,annual open enrollment period, which begins November ...
Cached Medicine News:Health News:TraceSecurity Announces Partnership with PHNS Expanding Compliance Services to Hundreds of Healthcare Systems 2Health News:TraceSecurity Announces Partnership with PHNS Expanding Compliance Services to Hundreds of Healthcare Systems 3Health News:New Investors Fund Expansion of Cavidi AB 2Health News:ULLICO Inc. and U.S. Department of Labor Agree to Resolve 5 Year Old ERISA Investigation 2Health News:ULLICO Inc. and U.S. Department of Labor Agree to Resolve 5 Year Old ERISA Investigation 3Health News:Charlie Rose Science Series 2Health News:HealthPartners is National Benchmark in Six Out of Seven Areas in National Business Coalition on Health Report 2Health News:Blue Cross and Blue Shield of Oklahoma Announces Flexible, Affordable Blue MedicareRx(SM) Medicare Prescription Drug Plans 2
Nucleus divider with 1.25 mm tip and blade offset at a 60 degree angle is ideal for performing the "Phaco Chop" technique to be used in left hand. Round knurled handle....
6 mm curved hook. Flat serrated handle with polished finish. Overall length: 4.7 inches. Most popular size or model....
Small bulbous tip with flat sides. Flat serrated handle with polished finish. Overall length: 5.1 inches....
7 mm flattened hook. Flat serrated handle with polished finish. Overall length: 4.9 inches....
Medicine Products: